Literature DB >> 20981678

Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations.

Harshabad Singh, Lillian Werner, Daniel Deangelo, Karen Ballen, Philip Amrein, Martha Wadleigh, Donna Neuberg, Edward Fox, Richard Stone, Eyal Attar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20981678      PMCID： PMC3501727          DOI： 10.1002/ajh.21867

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  22 in total

1.  Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.

Authors:  C Callens; S Chevret; J-M Cayuela; B Cassinat; E Raffoux; S de Botton; X Thomas; A Guerci; N Fegueux; A Pigneux; A-M Stoppa; T Lamy; F Rigal-Huguet; A Vekhoff; S Meyer-Monard; A Ferrand; M Sanz; C Chomienne; P Fenaux; H Dombret
Journal:  Leukemia       Date:  2005-07       Impact factor: 11.528

2.  Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA.

Authors:  J M Hernández; G Martín; N C Gutiérrez; J Cervera; M T Ferro; M J Calasanz; J A Martínez-Climent; E Luño; M Tormo; C Rayón; J Díaz-Mediavilla; M González; J D González-San Miguel; K Pérez-Equiza; C Rivas; J Esteve; M del C Alvarez; J Odriozola; J M Ribera; M A Sanz
Journal:  Haematologica       Date:  2001-08       Impact factor: 9.941

3.  Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.

Authors:  M A Sanz; F Lo Coco; G Martín; G Avvisati; C Rayón; T Barbui; J Díaz-Mediavilla; G Fioritoni; J D González; V Liso; J Esteve; F Ferrara; P Bolufer; C Bernasconi; M Gonzalez; F Rodeghiero; D Colomer; M C Petti; J M Ribera; F Mandelli
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

4.  Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia.

Authors:  Florian Kuchenbauer; Claudia Schoch; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

5.  Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

Authors:  Rosemary E Gale; Robert Hills; Arnold R Pizzey; Panagiotis D Kottaridis; David Swirsky; Amanda F Gilkes; Elizabeth Nugent; Kenneth I Mills; Keith Wheatley; Ellen Solomon; Alan K Burnett; David C Linch; David Grimwade
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

6.  FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact.

Authors:  Wing Y Au; Alvin Fung; Chor S Chim; Albert K Lie; Raymond Liang; Edmond S K Ma; Cheuk H Chan; Kit F Wong; Yok L Kwong
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

7.  FLT3 mutations in childhood acute lymphoblastic leukemia.

Authors:  Scott A Armstrong; Meghann E Mabon; Lewis B Silverman; Aihong Li; John G Gribben; Edward A Fox; Stephen E Sallan; Stanley J Korsmeyer
Journal:  Blood       Date:  2003-12-11       Impact factor: 22.113

8.  Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.

Authors:  N I Noguera; M Breccia; M Divona; D Diverio; V Costa; S De Santis; G Avvisati; M B Pinazzi; M C Petti; F Mandelli; F Lo Coco
Journal:  Leukemia       Date:  2002-11       Impact factor: 11.528

9.  FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.

Authors:  M Carmen Chillón; Carina Fernández; Ramón García-Sanz; Ana Balanzategui; Fernando Ramos; Javier Fernández-Calvo; Marcos González; Jesús F San Miguel
Journal:  Hematol J       Date:  2004

10.  PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors.

Authors:  Saverio Minucci; Silvia Monestiroli; Sabrina Giavara; Simona Ronzoni; Francesco Marchesi; Alessandra Insinga; Daniela Diverio; Patrizia Gasparini; Manuela Capillo; Emanuela Colombo; Cristian Matteucci; Francesco Contegno; Francesco Lo-Coco; Eugenio Scanziani; Alberto Gobbi; Pier Giuseppe Pelicci
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113
View more
  5 in total

1.  TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.

Authors:  Xiaopeng Tian; Yang Xu; Jia Yin; Hong Tian; Suning Chen; Depei Wu; Aining Sun
Journal:  Int J Hematol       Date:  2014-05-24       Impact factor: 2.490

2.  Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia.

Authors:  Geetanjali R Kamath; Douglas Tremblay; Alexander Coltoff; Jessica Caro; Guido Lancman; Sheena Bhalla; Vesna Najfeld; John Mascarenhas; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2019-07-04       Impact factor: 4.944

3.  High-Risk Acute Promyelocytic Leukemia with Unusual T/Myeloid Immunophenotype Successfully Treated with ATRA and Arsenic Trioxide-Based Regimen.

Authors:  Zeba N Singh; Vu H Duong; Rima Koka; Ying Zou; Sameer Sawhney; Li Tang; Maria R Baer; Nicholas Ambulos; Firas El Chaer; Ashkan Emadi
Journal:  J Hematop       Date:  2018-08-09       Impact factor: 0.196

4.  Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era.

Authors:  Maria Pagoni; Maria Garofalaki; Fotios Panitsas; Kalliopi Manola; Katerina Psarra; Panagiotis Economopoulos; Aggeliki Vourtsi; Marios Antoniades; Kostas Gkirkas; Evangelia Tzouvara; Fotis Katis; Chrystalla Prokopiou; Irene Tziotziou; Artemis Balta; Eleni Lemissiou; Panagiotis Tsirigotis; Panagiotis Repoussis; Nicolas Harhalakis
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-11-28       Impact factor: 2.576

Review 5.  The Impact of Flt3 Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis.

Authors:  Gledson L Picharski; Diancarlos P Andrade; Ana Luiza M R Fabro; Luana Lenzi; Fernanda S Tonin; Raul C Ribeiro; Bonald C Figueiredo
Journal:  Cancers (Basel)       Date:  2019-09-05       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.